Key Takeaways
- Syngenta Group reported Q1 2025 sales of $7.3 billion, down 1% YoY, but up 3% at constant exchange rates (CER).
- EBITDA rose 18% YoY to $1.4 billion, supported by strong Crop Protection performance and operational efficiencies.
- Crop Protection sales increased 5% (11% CER), with double-digit growth in North America and China.
- ADAMA and Seeds segments saw selective sales reductions as part of margin-focused strategies.
- Syngenta Biologicals, new product approvals, and innovation in seed traits contributed to overall resilience and growth.
Syngenta Group Delivers Strong Q1 2025 EBITDA Growth Amid Selective Market Adjustments
Syngenta Group (Profile) announced financial results for the first quarter of 2025, with sales totaling $7.3 billion, a slight decline of 1% compared to Q1 2024. However, on a constant exchange rate (CER) basis, sales increased by 3%, reflecting steady underlying business performance. The Group’s EBITDA increased by 18% to $1.4 billion, representing an improved EBITDA margin of 19.9%, up 3.2 percentage points year-over-year.
The performance was driven primarily by strong results in Crop Protection, continued growth in Syngenta Biologicals, and improved operational efficiency across business units.
Business Unit Performance
Syngenta Crop Protection
Crop Protection sales rose 5% to $3.4 billion (+11% CER), with strong market recovery in the U.S. and sustained demand in China. North America posted 20% sales growth, supported by stabilized channel inventories and demand for new technologies like ADEPIDYN®, PLINAZOLIN®, and TYMIRIUM®. Biologicals continued their growth trajectory, particularly in China and the U.S.
More than 250 product approvals were secured globally in Q1, including registrations for advanced insecticide and fungicide technologies in markets such as Ukraine, Vietnam, India, Oman, and Australia.
ADAMA
ADAMA recorded $1.0 billion in sales, down 5% YoY (-3% CER), reflecting a deliberate focus on higher-margin product lines. Despite lower top-line revenue, ADAMA achieved its fourth consecutive quarter of adjusted EBITDA growth, with improvements in net profit and free cash flow. Growth was seen in China (+8%) and North America (+15%), while Latin America and Asia Pacific faced currency and pricing headwinds.
Syngenta Seeds
Seeds revenue reached $1.4 billion, down 2% in USD (+1% CER). While Field Crop sales fell in the U.S., Brazil, and parts of Asia, China grew 18%, and Vegetables & Flowers saw a 4% increase. Notable R&D achievements included the launch of DURASTAK™, a triple Bt stack for corn rootworm resistance, and regulatory approvals in China for GM corn traits. A new R&D center in Hyderabad, India and land acquisition in Guatemala were also announced to support breeding acceleration and innovation.
Syngenta Group China
Sales in China fell 6% to $2.5 billion (-5% CER), as the company continued to streamline low-margin operations. However, Seeds (+19%), Crop Protection (+9%), and Crop Nutrition (+6%) all posted growth. Grain trading saw a sharp decline as part of the ongoing portfolio focus. Operational milestones included launch activities at Yangnong’s Huludao production center and development progress at the Yangling Breeding Innovation Center.
Outlook and Strategic Priorities
Syngenta Group continues to invest in R&D, regulatory expansion, and technology development, while maintaining focus on cost discipline, productivity, and cash flow optimization. Cash flow continued to improve in Q1 2025, supported by higher margins and more efficient working capital management.
The company expects further stabilization in both Crop Protection and Seeds markets and remains committed to long-term profitable growth through innovation, market expansion, and sustainability-focused solutions.
Read the entire financial results here.
6 Comments